Elisabeth G.E. de Vries

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

RECIST 1.1—Update and clarification: From the RECIST committee

Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries et al. · European Journal of Cancer · 2016 · 1.8K citations

Public Policy, Recist 1.1—Update, Law +2

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink et al. · Clinical Pharmacology & Therapeutics · 2010 · 792 citations

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Nathan I. Cherny, Richard Sullivan, Urania Dafni et al. · Annals of Oncology · 2015 · 792 citations · Full text

Oncology, Clinical Benefit Scale, Anti-cancer Therapies +8

Evidence Based Selection of Housekeeping Genes

Hendrik J.M. de Jonge, Rudolf S.N. Fehrmann, Eveline S.J.M. de Bont et al. · PLoS ONE · 2007 · 759 citations · Full text

Enhanced Stability, Genetics, Gene Characterization +20